Stock Analysis

Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt

Published
BOVESPA:BIOM3
Source: Shutterstock

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. We can see that Biomm S.A. (BVMF:BIOM3) does use debt in its business. But the real question is whether this debt is making the company risky.

When Is Debt A Problem?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. By replacing dilution, though, debt can be an extremely good tool for businesses that need capital to invest in growth at high rates of return. When we think about a company's use of debt, we first look at cash and debt together.

See our latest analysis for Biomm

How Much Debt Does Biomm Carry?

You can click the graphic below for the historical numbers, but it shows that Biomm had R$159.4m of debt in June 2023, down from R$172.4m, one year before. On the flip side, it has R$49.6m in cash leading to net debt of about R$109.7m.

debt-equity-history-analysis
BOVESPA:BIOM3 Debt to Equity History November 12th 2023

How Healthy Is Biomm's Balance Sheet?

The latest balance sheet data shows that Biomm had liabilities of R$78.8m due within a year, and liabilities of R$142.5m falling due after that. Offsetting this, it had R$49.6m in cash and R$33.2m in receivables that were due within 12 months. So it has liabilities totalling R$138.6m more than its cash and near-term receivables, combined.

Biomm has a market capitalization of R$478.8m, so it could very likely raise cash to ameliorate its balance sheet, if the need arose. But we definitely want to keep our eyes open to indications that its debt is bringing too much risk. The balance sheet is clearly the area to focus on when you are analysing debt. But you can't view debt in total isolation; since Biomm will need earnings to service that debt. So when considering debt, it's definitely worth looking at the earnings trend. Click here for an interactive snapshot.

Over 12 months, Biomm reported revenue of R$122m, which is a gain of 14%, although it did not report any earnings before interest and tax. We usually like to see faster growth from unprofitable companies, but each to their own.

Caveat Emptor

Over the last twelve months Biomm produced an earnings before interest and tax (EBIT) loss. Its EBIT loss was a whopping R$79m. When we look at that and recall the liabilities on its balance sheet, relative to cash, it seems unwise to us for the company to have any debt. Quite frankly we think the balance sheet is far from match-fit, although it could be improved with time. Another cause for caution is that is bled R$86m in negative free cash flow over the last twelve months. So suffice it to say we consider the stock very risky. The balance sheet is clearly the area to focus on when you are analysing debt. However, not all investment risk resides within the balance sheet - far from it. We've identified 5 warning signs with Biomm (at least 3 which are significant) , and understanding them should be part of your investment process.

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

Valuation is complex, but we're helping make it simple.

Find out whether Biomm is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis